Prevalence and Risk Factors of Clostridium difficile Infection Among Patients Hospitalized for a Flare of Inflammatory Bowel Disease in King Abdulaziz University Hospital.|https://dx.doi.org/10.7759/cureus.48451
Predictive value of fecal calprotectin and lactoferrin levels for negative outcomes in Clostridioides difficile infection.|https://dx.doi.org/10.1007/s10096-023-04729-z
Pulsed dosing and extended daily dosing of oral vancomycin do not facilitate clearance of Clostridioides difficile colonization in mice.|https://dx.doi.org/10.1128/aac.00903-23
A Comparison of the Efficacy of Treatment With Fidaxomicin Versus Vancomycin in Clostridioides difficile Infection.|https://dx.doi.org/10.7759/cureus.48735
Vowst's FDA approval is a boon for the prevention of recurrent Clostridioides difficile infection.|https://dx.doi.org/10.1097/MS9.0000000000001410
Update on Microbiota-derived therapies for recurrent Clostridioides difficile infections, 2023.|https://dx.doi.org/10.1016/j.cmi.2023.12.007
Microbiome-preserving antibiotics for the treatment of Clostridioides difficile infection: a systematic review and meta-analysis.|https://dx.doi.org/10.1007/s10151-023-02878-z
